Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Risk of secondary chronic myeloid leukemia in cancer survivors: A nationwide population-based study in Taiwan

View Full Paper
Ask AI
Bookmark
Share

Authors

CLChia-Jen Liu

Discussion

Loading...

Member takes

Overview

Retrospective cohort study found higher CML incidence in cancer survivors, linking male sex, diabetes, and heart failure to increased risk.

Key Points

  • Secondary chronic myeloid leukemia incidence was 2.55 per 100,000 person-years in cancer survivors, indicating significant risk.
  • Multivariate analysis identified male sex, diabetes mellitus, and heart failure as independent risk factors for developing secondary CML.
  • Utilizing Taiwan's National Health Insurance Research Database, we followed cancer survivors longitudinally for secondary CML development.
  • These findings highlight the need for ongoing monitoring of hematologic health in cancer survivors with specific tumors.

Cite This Study

Chia-Jen Liu (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd66https://doi.org/10.1182/blood-2025-1994
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Beyond survival in chronic myeloid leukemia: A systematic review of secondary malignancies in the era of tyrosine kinase inhibitors2025
  2. 2Risk of second primary malignancies among CLL survivors across treatment eras: A SEER-based study with racial and ethnic stratification2025
  3. 3The incidence, risk factors, and survival of acute myeloid leukemia secondary to chronic myelomonocytic leukemia: a population-based study2025
  4. 4Proportion of second hematologic malignancies linked to radiotherapy treatment in adults: A cohort study in the US SEER cancer registries 2001-20222025
  5. 5Risk of second primary hematological malignancy post chimeric antigen receptor T-cell therapy in diffuse large B-cell lymphoma: Propensity-matched analysis using trinetx database2025